U.S. FDA Broadens Indication for Verzenioยฎ (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.